(CercleFinance.com) – Erytech rose on the Paris Stock Exchange on Monday following the presentation at an ASCO symposium of the results of two clinical studies evaluating eryaspase, its flagship product, in the treatment of pancreatic cancer .
The first presentation, in the form of a poster, relates to updated data from a phase 1 study in combination with mFOLFIRINOX in patients with pancreatic cancer in first line.
The biotech emphasizes that these data confirm a good safety profile while demonstrating encouraging clinical activity.
An oral presentation of the complete results of the phase 3 study in the second-line treatment of metastatic pancreatic cancer, carried out as a ‘late-breaking’ abstract, confirmed the first results communicated in October 2021. , highlighting the potential benefit of eryaspase in a subset of chemotherapy-treated patients.
On the Paris Stock Exchange, Erytech shares rose 1% late Monday morning, after having climbed nearly 5% for a while, following these data unveiled at the symposium on gastrointestinal cancers in Paris. American Society of Clinical Oncology (ASCO GI).